Revance Therapeutics, Inc. (RVNC)
Stock Price:
$24.56 USD
0.19 (0.78%)
Updated Aug 12, 2020 1:50 PM EDT - Market open
Key Info
| Market Cap |
1.40B |
| Revenue (ttm) |
492,000 |
| Net Income (ttm) |
-209.26M |
| Shares Out |
65.78M |
| EPS (ttm) |
-4.25 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 12, 2020 |
| Last Price |
$24.56 |
| Previous Close |
$24.37 |
| Change ($) |
0.19 |
| Change (%) |
0.78% |
| Day's Open |
24.64 |
| Day's Range |
24.31 - 24.92 |
| Day's Volume |
99,774 |
| 52-Week Range |
9.88 - 27.97 |
More Stats
| Market Cap |
1.40B |
| Enterprise Value |
1.11B |
| Earnings Date (est) |
Oct 29, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
65.78M |
| Float |
54.12M |
| EPS (basic) |
-4.23 |
| EPS (diluted) |
-4.25 |
| FCF / Share |
-2.38 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
7.47M |
| Short Ratio |
13.51 |
| Short % of Float |
10.53% |
| Beta |
1.60 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
2,851.15 |
| PB Ratio |
5.57 |
| Revenue |
492,000 |
| Operating Income |
-206.78M |
| Net Income |
-209.26M |
| Free Cash Flow |
-128.84M |
| Net Cash |
293.13M |
| Net Cash / Share |
5.13 |
| Gross Margin |
83.94% |
| Operating Margin |
-42,027.44% |
| Profit Margin |
-42,532.10% |
| FCF Margin |
-26,187.60% |
| ROA |
-29.64% |
| ROE |
-94.21% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (11)
| Buy |
10 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$37.09*
(51.02% upside)
Low
23.0
Current: $24.56
High
56.0
Target: 37.09
*Average 12-month price target from 11 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 0.41 | 3.73 | 0.26 | 0.30 | 0.30 | 0.38 | 0.62 | 0.72 | 0.56 |
| Revenue Growth | -88.92% | 1323.28% | -12.67% | 0% | -21.67% | -37.93% | -13.95% | 28.73% | - |
| Gross Profit | 0.41 | 3.73 | 0.26 | 0.30 | 0.30 | 0.38 | 0.62 | 0.72 | 0.55 |
| Operating Income | -164 | -143 | -120 | -88.22 | -72.32 | -52.05 | -38.23 | -43.19 | -27.74 |
| Net Income | -159 | -143 | -121 | -89.27 | -73.48 | -62.92 | -52.45 | -58.26 | -44.86 |
| Shares Outstanding | 43.46 | 36.17 | 30.10 | 28.11 | 24.34 | 19.39 | 0.22 | 0.20 | 0.20 |
| Earnings Per Share | -3.67 | -3.94 | -4.01 | -3.18 | -3.02 | -3.24 | 1.05 | -290.48 | -226.06 |
| Operating Cash Flow | -106 | -104 | -95.34 | -59.83 | -55.67 | -55.07 | -47.76 | -38.91 | -28.41 |
| Capital Expenditures | -3.23 | -5.45 | -2.53 | -1.67 | -3.33 | -6.98 | -6.48 | -0.32 | -0.15 |
| Free Cash Flow | -109 | -110 | -97.87 | -61.50 | -59.00 | -62.05 | -54.24 | -39.23 | -28.56 |
| Cash & Equivalents | 291 | 177 | 283 | 186 | 252 | 171 | 3.99 | 4.16 | 29.70 |
| Total Debt | 29.34 | - | 1.87 | 5.35 | 8.48 | 3.54 | 25.49 | 106 | 68.99 |
| Net Cash / Debt | 262 | 177 | 282 | 181 | 244 | 168 | -21.50 | -102 | -39.29 |
| Assets | 340 | 226 | 296 | 204 | 276 | 192 | 22.65 | 13.42 | 39.93 |
| Liabilities | 115 | 80.73 | 26.85 | 27.29 | 22.57 | 16.10 | 56.21 | 135 | 99.98 |
| Book Value | 225 | 146 | 269 | 177 | 253 | 176 | -158 | -217 | -155 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Revance Therapeutics, Inc. |
| Country |
United States |
| Employees |
193 |
| CEO |
Mark J. Foley |
Stock Information
| Ticker Symbol |
RVNC |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: RVNC |
| IPO Date |
February 6, 2014 |
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI) which competed phase 3 clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; in phase 2 clinical trials to treat adult upper limb spasticity and plantar fasciitis, and in pre-clinical trials to treat chronic migraine. It is also developing DAXI for forehead lines, lateral canthal lines, and upper facial lines that is in phase 2 clinical trials; DaxibotulinumtoxinA Topical for therapeutic and aesthetic applications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration agreement with Mylan Ireland Limited for the development, manufacture, and commercialization of a biosimilar to BOTOX; and collaboration and license agreement with Mylan N.V. for the development and regulatory approval of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.